Latamoxef
Latamoxef (or moxalactam) is an oxacephem antibiotic usually grouped with the cephalosporins. In oxacephems such as latamoxef, the sulfur atom of the cephalosporin core is replaced with an oxygen atom.
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intramuscular, intravenous |
ATC code | |
Pharmacokinetic data | |
Protein binding | 35 to 50% |
Metabolism | Nil |
Elimination half-life | 2 hours |
Excretion | Mostly renal, unchanged; also biliary |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.059.334 |
Chemical and physical data | |
Formula | C20H20N6O9S |
Molar mass | 520.47 g·mol−1 |
3D model (JSmol) | |
Melting point | 117 to 122 °C (243 to 252 °F) (dec.) |
| |
| |
(what is this?) (verify) |
Latamoxef has been associated with prolonged bleeding time, and several cases of coagulopathy, some fatal, were reported during the 1980s. Latamoxef is no longer available in the United States. As with other cephalosporins with a methylthiotetrazole side chain, latamoxef causes a disulfiram reaction when mixed with alcohol. Additionally, the methylthiotetrazole side chain inhibits γ-carboxylation of glutamic acid; this can interfere with the actions of vitamin K.
It has been described as a third-generation cephalosporin.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.